2017.06.26

Dr. Lu Xianping from CHIPSCREEN BIOSCIENCES was elected as " the 2016 Annual Character of the Scientific Chinese."

Dr. Lu Xianping from CHIPSCREEN BIOSCIENCES was elected as " the 2016 Annual Character of the Scientific Chinese."

Full text

2017.06.22

CHIPSCREEN BIOSCIENCES 2017 HDACi regional summit was held smoothly

CHIPSCREEN BIOSCIENCES 2017 HDACi regional summit was held smoothly

Full text

2017.06.22

CHIPSCREEN BIOSCIENCES was invited to participate in 2017 China International Drug Information Conference and 9th DIA China Annual Meeting

CHIPSCREEN BIOSCIENCES was invited to participate in 2017 China International Drug Information Conference and 9th DIA China Annual Meeting

Full text

2017.05.19

Dr. Lu Xianping was invited to attend 2017 PKU diabetes forum

Dr. Lu Xianping was invited to attend 2017 PKU diabetes forum

Full text

2017.04.17

Phase III clinical trial of breast cancer approved by Taiwan TFDA in Chidamide

Phase III clinical trial of breast cancer approved by Taiwan TFDA in Chidamide

Full text

2017.03.30

Experts from World Health Organization visit CHIPSCREEN BIOSCIENCES

Experts from World Health Organization visit CHIPSCREEN BIOSCIENCES

Full text

2017.03.27

Dr. Lu Xianping was invited to attend 2017 Asia Pacific Drug Research and Development Leader Summit

Dr. Lu Xianping was invited to attend 2017 Asia Pacific Drug Research and Development Leader Summit

Full text

2017.03.13

Chidamide won the most clinically valuable innovative medicine of the second China Pharmaceutical Innovative Brand in 2016

Chidamide won the most clinically valuable innovative medicine of the second China Pharmaceutical Innovative Brand in 2016

Full text

2017.01.05

Our company has won the national titles of " high-tech enterprise" and " Shenzhen high-tech enterprise"

Our company has won the national titles of " high-tech enterprise" and " Shenzhen high-tech enterprise"

Full text

2016.12.27

As a representative of Pingshan's innovation drive, our company was reported by Guangming net and other media

As a representative of Pingshan's innovation drive, our company was reported by Guangming net and other media

Full text

2016.11.29

Phase III clinical trial of Chiglitazar, a new CHIPSCREEN BIOSCIENCES anti-type 2 diabetes drug, completed

Phase III clinical trial of Chiglitazar, a new CHIPSCREEN BIOSCIENCES anti-type 2 diabetes drug, completed

Full text

2016.11.29

The second HDACi ( histone deacetylase inhibitor ) summit was successfully held in Chengdu

The second HDACi ( histone deacetylase inhibitor ) summit was successfully held in Chengdu

Full text

2016.11.09

CHIPSCREEN BIOSCIENCES was invited to attend 2016 Huaxing Capital healthcare and life science and technology leader summit

CHIPSCREEN BIOSCIENCES was invited to attend 2016 Huaxing Capital healthcare and life science and technology leader summit

Full text

2016.11.09

CHIPSCREEN BIOSCIENCES was invited to DIA China's second drug research innovation conference

CHIPSCREEN BIOSCIENCES was invited to DIA China's second drug research innovation conference

Full text

2016.11.09

CHIPSCREEN BIOSCIENCES was invited to attend the first China oncology clinical trial summit

CHIPSCREEN BIOSCIENCES was invited to attend the first China oncology clinical trial summit

Full text